Answers are grounded in this paper and cite their sources.
Anabolic androgenic steroids (AASs) are synthetic derivatives of testosterone primarily indicated for the treatment of androgenic deficiency states. Non-clinical use of these agents has increased in recent years, particularly among athletes and individuals seeking rapid muscle hypertrophy and enhanced physical performance. Supraphysiological, off-label dosing is associated with significant systemic adverse effects. Elevated steroid levels disrupt endocrine homeostasis by suppressing the hypothalamic-pituitary-gonadal (HPG) axis. Furthermore, AAS misuse has been linked to dyslipidemia, activation of the renin-angiotensin-aldosterone system (RAAS), vascular remodeling, oxidative stress, and left ventricular hypertrophy. These mechanisms collectively add to structural remodeling of the myocardium and blood vessels, thereby increasing the risk of cardiovascular disease (CVD). Emerging evidence also indicates a higher prevalence of cardiomyopathy, arrhythmias, and premature atherosclerosis among chronic AAS users. Recent studies have associated AAS misuse with left ventricular dilation, reduced ejection fraction, and mitral regurgitation. This narrative review compiles current human-based research on the cardiovascular consequences of anabolic androgenic steroids misuse, explains the pathophysiology of CVD in this population, and highlights recommended clinical evaluations. A comprehensive literature search was executed using PubMed, Scopus, and Web of Science, focusing on original clinical cardiovascular imaging and translational studies published between 2000 and 2025.
No takes yet. Share an insight, caveat, or question.
Szołtys et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: